HUTCHMED's Sovleplenib NDA Accepted in China with Priority Review and Breakthrough Designation for wAIHA
HCM is trading near its 52-week low of $12.98 (4.7% above the low).
Summary
HUTCHMED announced that its New Drug Application for sovleplenib for warm antibody autoimmune hemolytic anemia (wAIHA) has been accepted for review by China's NMPA, receiving both Priority Review status and Breakthrough Therapy Designation.
Key Events · Product Development and Regulatory · HCM
-
NDA Accepted for Sovleplenib in China
The New Drug Application (NDA) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) has been accepted for review by the China National Medical Products Administration (NMPA).
-
Granted Priority Review Status
The NMPA has granted Priority Review status to the sovleplenib NDA, indicating an expedited review process due to its potential to address unmet medical needs.
-
Breakthrough Therapy Designation Confirmed
The NDA acceptance follows the NMPA's prior granting of Breakthrough Therapy Designation in March 2026 for sovleplenib in wAIHA, signifying its potential for significant advantages over existing therapies.
-
Second Indication for Sovleplenib
This is the second indication for which HUTCHMED has submitted an NDA for sovleplenib, following the NDA for immune thrombocytopenia (ITP) which also received priority review in February 2026, underscoring the drug's broad potential.
Analysis · HCM · Life Sciences
HUTCHMED has achieved a significant regulatory milestone with the acceptance of its New Drug Application (NDA) for sovleplenib in China for warm antibody autoimmune hemolytic anemia (wAIHA). The granting of both Priority Review status and Breakthrough Therapy Designation by the NMPA underscores the drug's potential to address a serious condition with unmet medical needs and indicates an expedited review pathway. This marks the second indication for which sovleplenib has received an NDA acceptance and priority review, highlighting the broad therapeutic potential of this novel Syk inhibitor and strengthening HUTCHMED's hematology portfolio. This positive development could serve as a significant catalyst, especially as the company's stock is currently trading near its 52-week low.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $13.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $12.98 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.